NeuroPulse Wk 44: Acumen’s Alzheimer’s Antibody Cleared Plaque and Missed on Cognition in 542 Patients
Plaque fell at both doses and cognition did not move. Acumen stopped sabirnetug, and BMS dropped an $80M Prothena antibody.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
The FDA Will Let One Licence Cover Patient-Specific Gene Edits, and CMS Is Taking Its Medicaid Gene Therapy Deals Beyond Sickle Cell
NICE Backed Arrowhead’s Plozasiran Eight Days After UK Authorisation, as a Cost Match for 57 to 114 People in England
Canada’s Drug Agency Has Drafted a Yes on Spinraza for Adults With SMA, Four Years After Telling Provinces Not to Pay
Enhertu Won EU Approval 39 Days After Its CHMP Opinion, and Payers Now Hold a Label Wider Than the Trial
China Approved Bayer’s Asundexian, the First Factor XIa Inhibitor, on a 26% Stroke Reduction, Three Years After It Lost to Apixaban
